Laprol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Laprol

What is Laprol?

Laprol is a pharmacological agent primarily utilized for its analgesic and antipyretic properties. It belongs to a class of medications designed to manage mild to moderate pain and assist in the reduction of elevated body temperature.

Composition and Mechanism

The active therapeutic components in Laprol work by interacting with specific chemical messengers in the central nervous system. By influencing the production of prostaglandins—substances associated with the body's response to injury or illness—the medication helps to elevate the overall pain threshold and modulate the thermal regulation center in the brain.

Common Applications

Laprol is frequently used to address various types of physical discomfort. Its application is common in the following contexts:

  • Pain Management: It is used to alleviate headaches, muscular aches, and discomfort associated with dental issues or minor injuries.
  • Fever Reduction: It serves as an intervention to temporarily lower a high body temperature resulting from common infections or inflammatory responses.
  • Chronic Conditions: In some instances, it may be used as a supportive treatment for ongoing conditions like osteoarthritis to help manage localized joint pain.

Characterization

Unlike some other pain-relieving medications, Laprol is generally characterized by its specific focus on pain and fever rather than significant anti-inflammatory action. This profile makes it a distinct option for patients who require symptom relief without the specific effects associated with other classes of analgesics.

What side effects are possible with Laprol?

Possible Side Effects and Safety Information

This section summarizes the adverse reactions and safety statements for Laprol as documented in official government regulatory information.

Frequency-Classified Adverse Reactions

Adverse events are categorized by frequency based on clinical trial data and post-marketing surveillance:

Classification Examples of Documented Adverse Reactions
Common Nausea, abdominal pain, diarrhea, constipation, and dizziness.
Rare/Very Rare Hypomagnesemia, bone fractures, acute kidney issues (Acute Tubulointerstitial Nephritis).

System-Organ-Class (SOC) Grouping

Reactions are officially grouped by the body system affected, including Gastrointestinal Disorders, Nervous System Disorders, Metabolism and Nutrition Disorders, and Musculoskeletal Disorders.

Serious Adverse Reactions

Regulatory documents list certain rare events as clinically significant or serious. These include severe hypomagnesemia, bone fractures (hip, wrist, spine), and documented instances of Clostridium difficile-associated diarrhea or Severe Cutaneous Adverse Reactions (SCARs).

Population and Exposure-Related Safety

  • Long-Term Exposure: Use for extended periods (typically exceeding one year) is associated with an increased risk of bone fractures and Vitamin B12 deficiency.
  • Severe Hepatic Impairment: Caution is required, and dose adjustment may be necessary for patients with severe liver disease.
  • Other Restrictions: Caution is advised when used alongside certain anti-HIV medicines, and close monitoring may be required for patients with risk factors for osteoporosis.

Overdose and Emergency Response

Laprol (Lansoprazole) is a Proton Pump Inhibitor (PPI) and, in large doses, an overdose is possible. While acute ingestion of large amounts often produces only mild symptoms, taking more than the prescribed dose may lead to serious health consequences, and immediate medical attention is necessary.

Symptoms of Laprol Overdose

Symptoms in cases of extreme overdose have included moderate but reversible effects, though severe cases may present more pronounced issues. Potential signs may include:

  • Gastrointestinal: Diarrhea, abdominal pain, nausea, and vomiting.
  • Neurological: Headache, dizziness, and confusion.
  • Other Potential Effects: Marked increases in heart rate (tachycardia) and sometimes severe elevation of blood pressure.

When to Seek Immediate Help

Call your local emergency services immediately if you or someone else has taken a dose of Laprol exceeding what was prescribed, even if the person appears well. Do not wait for symptoms to develop. It is critical to receive professional medical evaluation and management as soon as possible. Treatment for an overdose is typically supportive and symptomatic, administered in a hospital setting.

Emergency Indicators Action Required
Unconsciousness or unresponsiveness Call emergency services immediately
Severe or persistent vomiting/diarrhea Seek urgent medical care
Fast, irregular, or pounding heartbeat Seek urgent medical care

Therapeutic Uses of Laprol

What Laprol Treats: Main Uses and Benefits

Laprol is a prescription medication used to help manage symptoms associated with conditions caused by excessive stomach acid. Its primary therapeutic role is providing symptomatic relief for various gastrointestinal issues that stem from acid overproduction.

Laprol is indicated for several conditions. These include the short-term treatment of active duodenal ulcer, managing the effects of erosive esophagitis (EE), and the treatment of symptomatic gastroesophageal reflux disease (GERD). Additionally, it is used for the management of Zollinger-Ellison syndrome, a pathological hypersecretory condition.

In its therapeutic capacity, Laprol may support patients by helping to attain relief from associated symptoms, such as heartburn and other forms of digestive discomfort. Laprol may also help to support the management of active ulcers or erosive esophagitis.


Quick Fact: Relief for Heartburn

Laprol may provide relief for the symptoms of GERD, including heartburn.

Eligibility and Restrictions for Use

Eligibility for Laprol (Lansoprazole)

The use of Laprol is determined by official population eligibility rules defined in regulatory documents.

Approved Populations

Laprol is approved for use in adults and in pediatric patients aged 1 to 17 years for specific, approved indications. No routine dosage adjustment is necessary for patients with renal impairment or for the majority of older adults.

Absolute Contraindications (Who Must Not Use)

Laprol is contraindicated for patients with a known severe hypersensitivity to lansoprazole or to any component of the formulation. It is also prohibited for patients receiving Rilpivirine-containing products. Furthermore, certain formulations are contraindicated for patients with Phenylketonuria (PKU) or rare hereditary problems of sugar intolerance, such as fructose or sucrose intolerance, due to excipients [EMA SmPC].

Restricted and Conditional Use

The medicine is not recommended for pediatric patients younger than 1 year of age. Use is restricted and requires caution in patients with moderate to severe hepatic dysfunction (liver disease). For pregnant and nursing mothers, use is generally avoided or requires a clinical decision to discontinue the drug or discontinue breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Laprol (Lansoprazole) has officially documented interaction patterns structured primarily around two mechanisms: profound changes to gastric pH and interactions with the Cytochrome P450 (CYP) enzyme system.

Official Regulatory Interaction Profile

Interaction Entity Official Regulatory Statement
Contraindicated Combination Co-administration with Rilpivirine-containing products is formally prohibited due to the risk of substantially reducing Rilpivirine exposure.
Pharmacodynamic (pH-Dependent) Laprol significantly reduces the plasma concentration of drugs that require an acidic pH for absorption, including certain antiretroviral agents (e.g., Atazanavir) and antifungals (e.g., Ketoconazole).
Pharmacokinetic (Metabolic) Laprol inhibits CYP2C19, leading to an officially documented increase in exposure of co-administered CYP2C19 substrates, such as Cilostazol. Conversely, strong CYP3A4 inducers like St. John’s Wort significantly decrease Laprol's plasma concentrations.
Exposure-Modifying Substances Concomitant use with drugs like Tacrolimus and Digoxin can increase the blood concentrations of those agents. Post-marketing reports also document altered anticoagulation effects with Warfarin.
Timing Restriction Administration of Laprol must be separated from Sucralfate by at least 30 minutes to prevent the delay of Laprol absorption.

Population-Specific Interaction Notes

Official labeling notes that in patients with severe hepatic impairment, Laprol clearance is reduced, which results in increased drug exposure. Similarly, individuals classified as CYP2C19 poor metabolizers also exhibit a significantly higher Laprol exposure.

Mechanism of Action

How Laprol Works

Laprol works by engaging mechanisms that regulate the final step of acid production in the stomach, resulting in a sustained reduction of gastric acidity. The drug targets specific enzymes in the parietal cells to initiate a clear cascade of events that shape its physiological effect profile.

Irreversible Enzyme Inhibition of the Proton Pump

Laprol's primary action is its role as an irreversible inhibitor that acts on the H+/K+-ATPase enzyme (the proton pump). The drug is a prodrug that is selectively activated within the highly acidic environment of the parietal cell canaliculi. Upon activation, Laprol forms a covalent bond with cysteine residues on the key enzyme, which permanently inactivates the mechanism responsible for transporting hydrogen ions into the stomach. This critical molecular step modulates activity within the acid-secreting pathways.

Sustained Alteration of Gastric pH

This mechanistic cascade produces an alteration of the physiological activity of the stomach by elevating the pH level in the gastric lumen. Because the enzyme is permanently inactivated, acid secretion is disabled until the cell synthesizes new H^+/ K^+- ATPase enzyme. This duration of inhibition modifies the concentration of free hydrogen ions, which defines the resultant physiological changes that follow the mechanism of action.

Dosage and Administration Information

How to Use Laprol

Laprol (Lansoprazole) is administered primarily via the oral route in delayed-release forms, such as capsules or orally disintegrating tablets, but an intravenous (IV) infusion form is also available for use in specific clinical settings. The integrity of the oral form is crucial; the delayed-release pellets within the capsule must not be crushed, cut, or chewed, as this compromises the coating required for absorption.

Oral administration is standardized to occur at least 30 minutes before food, typically taken once daily in the morning. For patients who cannot swallow the capsule whole, the intact pellets may be mixed with a small amount of specific acidic juices or soft foods (e.g., applesauce or yogurt) and swallowed immediately.

Standard Dosing and Frequency

The dosage and duration of use are defined by the condition being managed. Most adult regimens utilize a once daily frequency, with doses commonly being 15 mg or 30 mg.

Usage Pattern (High-Level) Standard Adult Dose Typical Duration Pattern
Short-term Duodenal Ulcer 15 mg 4 weeks
Erosive Esophagitis (EE) 30 mg Up to 8 weeks
ZES (Initial/High-Dose) 60 mg qDay Long-term; doses >120 mg are divided

Population-Specific Use Adjustments

Specific modifications are used for certain patient groups. Individuals with severe hepatic impairment require a dose reduction to 15 mg once daily. Conversely, no dosage adjustment is necessary for older adults or patients with impaired kidney function. Dosing for children (1 to 11 years) is guided by body weight, often 15 mg or 30 mg qDay.

Missed Dose: If a dose is missed, it should be taken as soon as remembered, unless it is near the next scheduled dose, in which case the missed dose is skipped; the dose should not be doubled.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Laprol

Evidence for Healing Erosive Esophagitis (EE) and Preventing Relapse

Research for Laprol was studied for the short-term management of Erosive Esophagitis (EE). The foundational research primarily consists of short-term Randomized Controlled Trials (RCTs). These studies research examined the endoscopic healing rate, describing the proportion of adults where endoscopic healing was measured after a defined treatment interval, often 4 to 8 weeks. Patient-reported outcomes describing perceived discomfort were also monitored. Studies reported data patterns concerning the proportion of patients with endoscopic healing across the different treatment groups, including placebo. Laprol was also evaluated in long-term, placebo-controlled trials for the maintenance of healing in patients whose EE had already healed.

Research on Symptom Management for GERD and Ulcer Healing

Research explored the use of Laprol was studied for managing Symptomatic Gastroesophageal Reflux Disease (GERD), where studies examined outcomes related to physical discomfort. For active duodenal ulcers, Laprol was evaluated in short-term clinical trials. These studies research examined the endoscopic healing rate after approximately four weeks, focusing on adults with ulcers. Studies report data patterns related to the endoscopic healing proportions measured and research described how outcomes related to physical discomfort evolved. Evidence is limited for long-term outcomes specifically in non-erosive GERD.

Evidence for Pathological Hypersecretory Conditions

Research into rare conditions like Zollinger-Ellison Syndrome (ZES) relies on long-term observational studies and clinical follow-up. The research studies monitored the ability of Laprol to consistently achieve a target level of control of gastric acid output over many years. Because these studies are observational, results apply only to the populations studied, and the data available for long-term outcomes are not fully established compared to evidence from typical RCTs. Certainty remains low in a randomized sense.

Research Gaps and Remaining Uncertainties

Documented limitations exist in the evidence landscape. The research explored atypical symptoms as an outcome, where findings were mixed in some randomized trials. Certainty remains low for this specific use. Comparative evidence is lacking for definitive, long-term, head-to-head comparisons against every similar medication. Evidence quality varies across studies when non-randomized observational designs are used, which is necessary for rare conditions.

Key Studies & References

  1. The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis (Study M94-140 Open-Label Extension)
  2. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer - Database of Abstracts of Reviews of Effects (DARE) - NCBI

Frequently Asked Questions (FAQ)

Common questions about Laprol (FAQ)


Q: How quickly does Laprol start to show its effects?

Official studies indicate that the acid-suppressing effects of Laprol typically begin within one to two hours after the first dose. However, the maximum sustained reduction in stomach acid, which leads to the full therapeutic effect, is usually achieved after three to four days of continuous daily treatment.


Q: Can taking Laprol cause weight changes or fluid retention?

According to the official product information, weight changes (either an increase or decrease) and edema (fluid retention) are documented as uncommon adverse reactions. These effects are classified under the Metabolism and Nutrition Disorders section in regulatory documents.


Q: Does Laprol affect sleep or cause insomnia?

Yes, official regulatory information indicates that insomnia, or difficulty sleeping, is listed as an uncommon adverse reaction associated with Laprol use. Other effects related to the central nervous system are also documented in the product label.


Q: Can I consume alcohol while undergoing treatment with Laprol?

Regulatory texts do not currently list a specific, formal interaction between Laprol and alcohol. However, it is generally recommended that individuals discuss alcohol consumption with a healthcare provider.


Q: Does Laprol interact with hormonal contraceptives (birth control)?

Regulatory documents indicate that Laprol may influence the metabolism of certain hormonal contraceptives. Despite this potential interaction, the overall contraceptive effect is not typically expected to be significantly reduced.


Q: Is Laprol a controlled substance or habit-forming?

Laprol is not classified as a controlled substance by regulatory agencies. Therefore, according to government drug classifications, the medicine is not considered to be habit-forming or possess potential for abuse.


Q: Is it necessary to have a special lab test before starting Laprol?

Official documentation does not typically mandate a routine laboratory test for all patients before starting Laprol. Regulatory information notes that clinical consideration may be necessary for conditions like severe liver impairment.


Q: Does Laprol require a prescription, or is it available over the counter?

Laprol is available in both prescription-only strengths and specific over-the-counter (OTC) strengths. The availability of the OTC form is determined by the regulatory status in each country for specific uses and shorter treatment durations.


Q: Does Laprol cause hair loss or changes in skin appearance?

Alopecia (hair loss) is listed in regulatory documents as a rare adverse reaction to the medicine. Other changes in skin appearance, including rash and specific severe reactions, are also documented by official safety information.


Q: Is blurred vision listed as a potential side effect of Laprol?

Yes, official regulatory information documents blurred vision or other visual disturbances as rare adverse reactions associated with the use of Laprol. This is noted under the Eye Disorders section of the product labeling.


Q: Does Laprol affect cholesterol or blood sugar levels?

According to regulatory reports, rare adverse reactions documented under Metabolism and Nutrition Disorders include changes to blood sugar levels (hypoglycemia or hyperglycemia) and altered cholesterol/lipid levels.


Q: Does Laprol affect the immune system?

While Laprol's main action is not directly related to the immune system, regulatory documents list rare adverse reactions concerning the blood and lymphatic system. These effects are related to the blood and lymphatic system and include changes in white blood cell counts.


Q: Does Laprol interact with common over-the-counter pain relievers?

Regulatory documents describe a need for clinical consideration when Laprol is used concurrently with certain non-steroidal anti-inflammatory drugs (NSAIDs). This is due to a documented potential for an increased risk of gastrointestinal side effects when these medicines are taken together.


Q: Are there specific foods or supplements that should be avoided with Laprol?

Official regulatory guidance states that St. John’s Wort should be avoided, as it may significantly decrease the medicine's plasma concentration and effectiveness. Additionally, the delayed-release capsule form of Laprol must not be crushed or chewed.


Q: Why do some users report that Laprol did not work for their condition?

Official product documents cite conditions that can lead to varied responses, such as individual differences in how the body processes the medicine. For example, some individuals are classified as 'poor metabolizers,' which can result in reduced drug exposure and variable effectiveness.


Q: Can Laprol be taken at the same time as my other morning medications?

Laprol must be taken 30 minutes before food and requires a separation of at least 30 minutes from the medication Sucralfate. Aside from this specific restriction and its timing relative to food, Laprol can generally be taken with other non-interacting medications.


Q: What is the chance of getting a rash while on Laprol?

Regulatory reports indicate that a general rash or urticaria (hives) is documented as an uncommon adverse reaction. The documents also note the existence of more severe skin reactions, which are classified as rare.

--UNSAFE

Q: Are there any restrictions on driving or operating machinery while using Laprol?

Official documentation states that clinical consideration is necessary regarding driving or operating machinery. This is because documented common and uncommon side effects, such as dizziness or blurred vision, could potentially impair the ability to perform these tasks safely.


Q: What happens in the body when Laprol is stopped suddenly?

Because Laprol works by permanently blocking acid production (irreversible inhibition), stopping the medicine suddenly may cause a temporary, increased return of acid secretion. This physiological effect is described in clinical literature as rebound acid hypersecretion.


Q: What ingredients are contained in Laprol besides the main active component?

Official labeling documents provide a complete list of all non-active ingredients, known as excipients. This list is important because some Laprol formulations contain specific sugars that are contraindicated for patients with rare hereditary problems of sugar intolerance.

How should Laprol be stored and disposed of?

Storage and Disposal Requirements

Laprol (Lansoprazole) must be stored and handled according to the conditions required by regulatory agencies to maintain its stability and effectiveness.

Storage Scope Requirements
Temperature and Environment Store at controlled room temperature (20 C to 25 C) and do not freeze [1.2, 1.1]. The product must be protected from light and moisture [1.2, 2.6].
Container and Safety Keep the medicine in its original container and the container must remain tightly closed [1.3, 2.7]. It must always be stored out of reach of children [1.4].
Disposal Instructions Unused or expired Laprol should be disposed of by using an authorized drug take-back program [1.5]. If a take-back location is unavailable, mix the medicine with an unappealing substance (like dirt), seal it in a container, and place it in the household trash [1.5]. Do not dispose of the medicine into wastewater or sewage systems [1.6].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Laprol found in:

A-Z Index: